1Raphael F, Charlotte H, Malcolm K. Cancer vaccine [ J]. Hemalology/Oncology Clinics d North America, 2001, 15 (4) : 741-773.
2Fmncine M. Inmmnololgic mechaniam d antitumor activity [J]. Seminars in Oncology,2002, 29:5-11 (suppl 7).
3MamoA, KinnearB, IakeRA, etal. Tumor-specific CD4 ( + ) T ceils have a major "Post-Licensing" role in CTL mediuted antitumor immunity [ J ]. J Inmmnol, 2000,165: 6047-6055.
4Jesn-Frsnads F, Marie L, Nina B. Interaetions between dead cells and dendritic cells in the induction of antiviral CTL responses [ J ].Current Opinion in Immunology, 2001, 14:471-477.
5Lawarence F, Edgar G. Dendritic cells in cancer immunotherapy[J ]. Annu Rev Immunol,2000, 18: 245-273.
6Curti A, Fogli M, Ratta M, et al. Dendritic cell differentiation from hematopoietic CD34+progenitor cells[J]. J Biol Regul,Homeost A gents. 2001, 15: 49-52.
7Tarte K, Klein B. Dendritic cell-based vaccine:a promising approach for cancer immunotherapy[J]. Leukemia,1999, 13: 653-663.
8Carole L, An-L X, Douglas H, etal. Induction of human tumor-loaded dendritic cells[J]. lnt J Cancer,2001, 91: 438-447.
9Titzer S, Christensen O, Mmzke O, et al.Vanccination of mutiple myeloma patients with idiotype-pulsed dendritic cells:immunological and clinical aspects[J].British J Hemato,2000, 108: 805-816.
10Brossart P, Wirths S, Stnhle G, et al. Induction of Cytotoxic T-lymphocyte Responses in Vivo after Vaccinations with Peptide-plused Dendritic Cells [ J ]. Blood, 2000, 96:3102-3108.
